ASX - By Stock
|
IMM |
Re:
Ann: Ceasing to be a substantial holder
|
|
Ysardine
|
11 |
5.0K |
12 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
11
|
5.0K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene to present at 2024 Cholangiocarcinoma Conference
|
|
Ysardine
|
221 |
100K |
22 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
221
|
100K
|
22
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Final Director's Interest Notice MB
|
|
Ysardine
|
16 |
5.7K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
16
|
5.7K
|
1
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Final Director's Interest Notice MB
|
|
Ysardine
|
16 |
5.7K |
0 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
16
|
5.7K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Ysardine
|
23K |
11M |
12 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
23K
|
11M
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Ysardine
|
2.7K |
1.0M |
18 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
2.7K
|
1.0M
|
18
|
|
ASX - By Stock
|
IMM |
Re:
Ann: First Clinical Data announced from 90mg Dosing of Efti
|
|
Ysardine
|
56 |
30K |
17 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
56
|
30K
|
17
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Ysardine
|
80 |
39K |
11 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
80
|
39K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Ysardine
|
23K |
11M |
29 |
07/01/24 |
07/01/24 |
ASX - By Stock
|
23K
|
11M
|
29
|
|
ASX - By Stock
|
IMM |
Re:
The reason for the price increase ???
|
|
Ysardine
|
19 |
10K |
19 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
19
|
10K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Ysardine
|
2.7K |
1.0M |
23 |
16/12/23 |
16/12/23 |
ASX - By Stock
|
2.7K
|
1.0M
|
23
|
|
ASX - By Stock
|
IMU |
Re:
Ann: New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS
|
|
Ysardine
|
74 |
30K |
21 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
74
|
30K
|
21
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Ysardine
|
693 |
277K |
2 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
693
|
277K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
IMU product line - PD1-Vaxx
|
|
Ysardine
|
44 |
20K |
8 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
44
|
20K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Ysardine
|
693 |
277K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
693
|
277K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: AGM Presentation
|
|
Ysardine
|
217 |
105K |
21 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
217
|
105K
|
21
|
|
ASX - By Stock
|
ACL |
Re:
Ann: Fourth Supplementary Bidder's Statement
|
|
Ysardine
|
2 |
1.5K |
6 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
2
|
1.5K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Lead-in phase completed for ph2/3 trial in Breast Cancer
|
|
Ysardine
|
1 |
1.4K |
11 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
1
|
1.4K
|
11
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer to raise approximately $10 million
|
|
Ysardine
|
99 |
31K |
6 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
99
|
31K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Ysardine
|
2.7K |
1.0M |
13 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
2.7K
|
1.0M
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep reports promising data from INSIGHT-003 trial
|
|
Ysardine
|
10 |
5.3K |
21 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
10
|
5.3K
|
21
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep reports promising data from INSIGHT-003 trial
|
|
Ysardine
|
10 |
5.3K |
39 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
10
|
5.3K
|
39
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Ysardine
|
13K |
6.4M |
28 |
22/10/23 |
22/10/23 |
ASX - By Stock
|
13K
|
6.4M
|
28
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Ysardine
|
2.7K |
1.0M |
14 |
22/10/23 |
22/10/23 |
ASX - By Stock
|
2.7K
|
1.0M
|
14
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Dosing completion in Phase 1A brain cancer clinical trial
|
|
Ysardine
|
34 |
10K |
11 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
34
|
10K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
City of Hope cancer treatment
|
|
Ysardine
|
47 |
24K |
17 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
47
|
24K
|
17
|
|
ASX - By Stock
|
DUB |
Re:
Ann: Dubber raises $10.25 million in equity capital
|
|
Ysardine
|
28 |
12K |
1 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
28
|
12K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Ysardine
|
13K |
6.4M |
18 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
13K
|
6.4M
|
18
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
|
|
Ysardine
|
155 |
78K |
15 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
155
|
78K
|
15
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Change of Director's Interest Notice
|
|
Ysardine
|
222 |
88K |
30 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
222
|
88K
|
30
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Initial Director's Interest Notice
|
|
Ysardine
|
71 |
29K |
40 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
71
|
29K
|
40
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
|
|
Ysardine
|
233 |
108K |
47 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
233
|
108K
|
47
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Ysardine
|
693 |
277K |
5 |
12/06/23 |
12/06/23 |
ASX - By Stock
|
693
|
277K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results
|
|
Ysardine
|
439 |
228K |
13 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
439
|
228K
|
13
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results
|
|
Ysardine
|
439 |
228K |
120 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
439
|
228K
|
120
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Publication of Abstracts for ASCO 2023 Annual Meeting
|
|
Ysardine
|
29 |
14K |
21 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
29
|
14K
|
21
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Ysardine
|
13K |
6.4M |
11 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
13K
|
6.4M
|
11
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC
|
|
Ysardine
|
27 |
15K |
6 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
27
|
15K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP
|
|
Ysardine
|
20 |
7.1K |
7 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
20
|
7.1K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
CHM board Please delist from asx and transfer to US
|
|
Ysardine
|
5 |
2.6K |
2 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
5
|
2.6K
|
2
|
|
ASX - By Stock
|
DUB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Ysardine
|
42 |
24K |
1 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
42
|
24K
|
1
|
|
ASX - By Stock
|
RAD Biotech |
Re:
RAD media and Publications
|
|
Ysardine
|
176 |
71K |
1 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
176
|
71K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Deals v Share Price
|
|
Ysardine
|
124 |
55K |
73 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
124
|
55K
|
73
|
|
ASX - By Stock
|
ANZ |
Re:
ANZ - General Discussion
|
|
Ysardine
|
173 |
92K |
5 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
173
|
92K
|
5
|
|
ASX - By Stock
|
CSS |
Re:
Ann: Change of Director's Interest Notice - K Adams
|
|
Ysardine
|
1 |
1.7K |
2 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
1
|
1.7K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
March Roadshows
|
|
Ysardine
|
387 |
173K |
0 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
387
|
173K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Enrolment Target Reached for INSIGHT-003 Trial in NSCLC
|
|
Ysardine
|
2 |
1.8K |
26 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
2
|
1.8K
|
26
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD201 HER2 nanobody demonstrates favourable tumor targeting
|
|
Ysardine
|
15 |
6.4K |
3 |
16/12/22 |
16/12/22 |
ASX - By Stock
|
15
|
6.4K
|
3
|
|
ASX - By Stock
|
CSS |
Re:
Ann: Change of Director's Interest Notice - T Dillon
|
|
Ysardine
|
1 |
1.0K |
1 |
09/12/22 |
09/12/22 |
ASX - By Stock
|
1
|
1.0K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia
|
|
Ysardine
|
71 |
38K |
44 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
71
|
38K
|
44
|
|